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Since its discovery as the elusive tumor suppressor gene at the frequently mutated 10q23 locus, 
PTEN has been identified as lost or mutated in several sporadic and heritable tumor types. A 
decade of work has established that PTEN is a nonredundant phosphatase that is essential for 
regulating the highly oncogenic prosurvival PI3K/AKT signaling pathway. This review discusses 
emerging modes of PTEN function and regulation, and speculates about how manipulation of 
PTEN function could be used for cancer therapy.PTEN (phosphatase and tensin homolog deleted on chromosome 
10) is one of the most frequently mutated tumor suppressor genes 
in human cancer. PTEN was first discovered by independent 
groups and recognized as the frequently lost tumor suppressor 
gene on human chromosome 10q23, a locus that is highly suscep-
tible to mutation in primary human cancers (Li et al., 1997; Steck 
et al., 1997). The frequency of monoallelic mutations at this locus 
has been estimated at 50%–80% in sporadic tumors (including 
endometrial carcinoma, glioblastoma, and prostate cancer) and 
at 30%–50% in breast, colon, and lung tumors. Complete loss 
of PTEN is observed at highest frequencies in endometrial can-
cer and glioblastoma and is generally associated with advanced 
cancers and metastases (Ali et al., 1999). A recent landmark study 
reveals that PTEN loss is a common event in breast cancers 
caused by BRCA1 deficiency (Saal et al., 2008).
The importance of PTEN as a tumor suppressor is further 
supported by the study of PTEN germline mutations in a group 
of autosomal dominant syndromes characterized by develop-
mental disorders, neurological deficits, multiple hamartomas, 
and an increased risk of breast, thyroid, and endometrial can-
cers. Collectively, these are referred to as the PTEN hamar-
toma tumor syndromes (PHTS), which include Cowden syn-
drome, Lhermitte-Duclos disease, Bannayan-Riley-Ruvalcaba 
syndrome, and Proteus and Proteus-like syndromes. Various 
mouse models in which Pten is deleted also demonstrate the 
crucial role of PTEN as a tumor suppressor in multiple tumor 
types (Di Cristofano et al., 1998; Podsypanina et al., 1999; 
Suzuki et al., 1998; Trotman et al., 2003; Wang et al., 2003).
Functionally, PTEN is a nonredundant, plasma-membrane 
lipid phosphatase that antagonizes the phosphatidylinositol-3
-kinase (PI3K) signaling pathway (Maehama and Dixon, 1998; 
Stambolic et al., 1998). Upon stimulation of cells with growth 
stimuli, class I PI3K family members catalyze the conversion 
of phosphatidylinositol 4,5-bisphosphate (PIP2) to phosphati-
dylinositol 3,4,5-trisphosphate (PIP3), a second messenger 
that promotes survival, growth, and proliferation. Specifically, 
PTEN hydrolyzes the 3-phosphate on PIP3 to generate PIP2, and 
thereby negatively regulates PIP3-mediated downstream signal-
ing. Through its role in phosphatidylinositol homeostasis, PTEN 
is implicated in cell polarity and migration and thereby provides a potential link between outer membrane phospholipids and 
pathways that lead to cytoskeleletal reorganization (reviewed in 
Franca-Koh et al., 2007; see also the SnapShot by A. Carracedo, 
L. Salmena, and P.P. Pandolfi on the last page of this issue).
Upon PTEN loss, PIP3 accumulates and promotes the 
recruitment of a subset of proteins that contain a pleckstrin 
homology domain to cellular membranes, including the ser-
ine/threonine kinases AKT1, AKT2, AKT3, and PDK1. Once 
positioned at cell membranes, AKT isoforms are activated 
by phosphorylation at two different residues. AKT is thought 
to be phosphorylated by PDK1 on Thr308 and by the mTOR 
kinase complex 2 (mTORC2) on Ser473 (as reviewed in Guer-
tin and Sabatini, 2007; Manning and Cantley, 2007). Termina-
tion of AKT signaling is thought to be elicited by the protein 
phosphatase PHLIPP, which directly dephosphorylates phos-
pho-Ser473 on AKT (Brognard et al., 2007; Gao et al., 2005). 
Activation of AKT kinases promotes cell survival, proliferation, 
growth, angiogenesis, and cellular metabolism through phos-
phorylation of myriad cellular substrates including MDM2, 
GSK3, FOXO, BAD, CASP9, and p27 (Manning and Cantley, 
2007). AKT activation also leads to activation of the mTOR 
kinase complex 1 (mTORC1) through an inhibitory phosphory-
lation of the TSC tumor suppressor complex and consequent 
activation of RHEB, a Ras-related small GTPase (Guertin 
and Sabatini, 2007). As a consequence of PTEN inactivation, 
activation of mTORC1 in turn leads to enhanced translation 
of mRNA into protein, a hallmark of many cancers (Tee and 
Blenis, 2005). In addition to being repressed by a number of 
tumor suppressor genes directly implicated in human cancer, 
the mTOR arm of the PTEN/PI3K/AKT pathway is emerging 
as an effective target for anti-cancer agents, especially in 
tumors in which the activity of the mTOR pathway is elevated 
(Faivre et al., 2006; Guertin and Sabatini, 2007).
Many important publications have expertly reviewed the 
wide spectrum of mutations found in the PTEN gene and the 
multitude of tumor types that arise upon loss of PTEN activity. 
Also, the contribution of PTEN loss to activation of the PI3K/
AKT signaling pathway and consequent tumorigenesis is well 
established. In this review, we present emerging tenets for the 
regulation of the PTEN gene and PTEN protein, discuss uncon-Cell 133, May 2, 2008 ©2008 Elsevier Inc. 403
ventional downstream effectors and pathways of PTEN func-
tion, and introduce new potential strategies for PTEN-associ-
ated cancer therapies.
Functional PTEN Dose Dictates Cancer Susceptibility
The classical premise of tumor suppression asserts that both 
copies of a given tumor suppressor gene must be lost for can-
cer to arise (Knudson, 1971). Although this is definitely the case 
in certain circumstances and in particular tissue types (such 
as in a large fraction of retinoblastoma [RB] lesions that experi-
ence homozygous loss of the RB gene), heterozygous loss of 
other tumor suppressor genes can have critical biological con-
sequences toward cancer initiation and progression.
Loss of only one allele of Pten in mice has been shown to pro-
mote the progression of a lethal polyclonal autoimmune disorder 
with high penetrance (Di Cristofano et al., 1999), thereby sug-
gesting that Pten is functionally haploinsufficient (that is that one 
functional allele is not enough to sustain a wild-type condition). 
Similarly, Pten heterozygosity appears to be the driving force for 
epithelial cancers, such as prostate cancer, in mouse models of 
Figure 1. A Continuum of Functional PTEN Loss
We propose that loss of PTEN function by various molecular mechanisms can 
create gradations of tumor suppression. PTEN function can be compromised 
via genetic mutations, which result in a stepwise loss of PTEN function to pro-
duce states where there is either 50% (heterozygous) or 100% (homozygous) 
loss. Mechanisms including transcriptional repression, posttranslational mod-
ification, epigenetic silencing, and aberrant localization of PTEN can cause 
subtle and/or dramatic losses of PTEN functionality. Overall, a combination of 
these events produces a continuum of functional PTEN loss. Pten is haploin-
sufficient for tumor suppression in mice; therefore, 50% of total PTEN is not 
sufficient for tumor suppression. Whether this is the case in humans remains 
to be determined. When PTEN levels approach complete loss of expression, 
cells with intact p53 signaling trigger a strong cellular senescence program, 
thus acting as a brake on tumor progression.404 Cell 133, May 2, 2008 ©2008 Elsevier Inc.Pten loss (Di Cristofano et al., 2001). Moreover, our group has 
demonstrated that cellular levels of Pten protein inversely cor-
relate with the occurrence of invasive prostate cancer (Figure 1). 
This was established by generating a so-called “hypomorphic 
Pten allelic series” in the mouse where Pten dose is progres-
sively decreased below heterozygous levels (Trotman et al., 
2003). This suggests that Pten is a haploinsufficient tumor sup-
pressor gene in specific mouse tissues.
Despite evidence from mouse models, whether PTEN is a 
haploinsufficient tumor suppressor gene in humans remains 
to be determined. To date, there are only a handful of reports 
that provide support for this notion. By definition, PTEN is 
haploinsufficient for the development of PTEN hamartoma 
tumor syndrome, given that heterozygosity leads to charac-
teristic phenotypes, including various developmental disor-
ders and benign polyps. With respect to its role as a tumor 
suppressor, the increased susceptibility of patients with 
PTEN hamartoma tumor syndrome to develop tumors may 
be consistent with haploinsufficiency. Further support for 
haploinsufficiency is provided by the observation that some 
tumors derived from patients with Cowden syndrome do not 
have detectable biallelic mutation of the PTEN gene (Dahia, 
2000; Marsh et al., 1998). Moreover, primary prostate tumors 
often show loss or alteration of one PTEN allele at presenta-
tion (as in 70%–80% of cases of primary prostate cancer 
[Gray et al., 1998; Whang et al., 1998]) whereas homozygous 
inactivation is observed at much lower frequencies. Similarly 
in breast cancer, there is a lack of concordance between the 
occurrence of monoallelic mutation of PTEN (30%–40%) and 
the occurrence of biallelic loss (5%) (Ali et al., 1999; Bose 
et al., 1998; Feilotter et al., 1999). Indeed, complete loss of 
PTEN is observed in many advanced cancers. However, the 
observation that monoallelic mutation of PTEN without loss 
or mutation of the second allele is prevalent in breast and 
prostate cancer lesions is consistent with the notion that 
monoallelic loss of PTEN is sufficient for tumor initiation 
and progression. Overall, the question of PTEN haploinsuf-
ficiency remains an important one, and the analysis of more 
tumor samples is required to clarify whether, and in which 
types of human tissue, PTEN haploinsufficiency is critical.
In line with the notion that PTEN haploinsufficiency contrib-
utes to tumor progression, there are indications that even a minor 
impairment in PTEN function may lead to the development of 
cancer. This is illustrated by the identification of Cowden syn-
drome and tumor-derived PTEN mutations that preserve partial 
or even full PTEN lipid phosphatase function (Waite and Eng, 
2002). For example, some C2-domain mutations in PTEN iden-
tified in Cowden syndrome as well as other somatic mutations 
that produce C-terminal truncations retain phosphatase activity 
in biochemical assays (Han et al., 2000; Waite and Eng, 2002). 
These truncations ultimately affect PTEN phosphorylation, stabil-
ity and protein-protein interactions by deletion of phosphorylated 
residues and the PDZ domain. Moreover, N-terminal mutants are 
thought to influence PTEN stability yet maintain catalytic activity 
(Han et al., 2000), and point mutations of the central C2 domain 
have been demonstrated to impact proper PTEN localization 
(Trotman et al., 2007). Nevertheless, it must be noted that even 
though partially functional mutants do indeed exist, the major-
ity of PTEN mutations are believed to profoundly inhibit catalytic 
activity. In conclusion, that a partially functional allele of PTEN 
exists in heterozygosity in disorders that confer increased cancer 
susceptibility (as observed in PTEN hamartoma tumor syndrome) 
may point toward a critical role for slight and selective functional 
impairment of PTEN in tumor susceptibility.
This notion is timely and particularly relevant given that 
mechanisms for PTEN control at the transcriptional and 
posttranslational levels may be altered in disease. Moreover, 
mutants of PTEN that maintain partial function may have a 
selective advantage over mutants that confer a complete loss 
of function, because complete loss of PTEN induces the acti-
vation of a p53-dependent cellular senescence response, as 
discussed below (Chen et al., 2005).
PTEN and Cellular Senescence
While studying the relationship between Pten dose and tumor 
progression in mouse models of prostate specific loss of Pten, 
Chen et al. (2005) observed an unexpected and intriguing phe-
nomenon: complete acute loss of Pten did not provide a prolif-
erative advantage as would be expected, but instead promoted 
a strong senescence response that opposed tumor progression. 
Senescence, a cellular program that triggers an irreversible growth 
arrest and limits the replicative life span of cultured primary cells, 
has been proposed to function as an anti-tumor mechanism set 
off by tumor suppressor genes in response to triggers including 
DNA damage and oncogene activation (Campisi and d’Adda di 
Fagagna, 2007).
Mice with conditional inactivation of Pten in the prostate 
develop invasive cancer; however early-stage tumor develop-
ment has been associated with slow growth, increased p53 
levels, and cellular senescence. As predicted from these find-
ings, combined inactivation of Pten and Trp53 leads to uncon-
strained tumor growth as demonstrated by the generation of 
massive invasive prostate tumors. This implies that complete 
ablation of PTEN can be detrimental to tumor growth in the 
absence of other mutations and highlights the importance 
of haploinsufficiency or partial PTEN impairment in tumor 
progression (Figure 1). Clinically, these findings provide an 
explanation as to why complete PTEN loss is not frequently 
observed at cancer presentation and, importantly, imply that 
PTEN-deficient prostate cancer may benefit from drugs that 
can promote p53 activation and enhancement of p53-depen-
dent cellular senescence.
Regulating the PTEN Message
Genetic loss or mutation of tumor suppressor genes is a frequent 
event initiating and/or promoting tumorigenesis (Vogelstein and 
Kinzler, 2004). Tumour suppressor genes are also subject to 
countless regulatory mechanisms including epigenetic effects, 
transcriptional modulation, and posttranscriptional and post-
translational modifications that ultimately govern protein levels, 
activity, localization, binding partners, and function. Disrupted 
tumor suppressor regulation by one or more of these mecha-
nisms may also have catastrophic consequences for a cell.
In addition to mutations that partially or fully inactivate a 
given PTEN allele, emerging evidence shows that complete 
or partial loss of PTEN protein expression, through as-yet-un-identified mechanisms, can impact tumor suppression (Figure 
2A). For instance, spontaneous cancers that harbor monoal-
lelic mutations of PTEN possess at least one functional wild-
type PTEN allele, yet they further or completely lose PTEN pro-
tein immunoreactivity in the absence of detectable mutations 
of the remaining PTEN allele (Leupin et al., 2003; Mutter et al., 
2000; Shi et al., 2003; Zhou et al., 2002). These observations 
imply that epigenetic silencing by aberrant promoter methyla-
tion, deregulated transcription, increased degradation, and/or 
mislocalization of the PTEN protein may disrupt function and 
promote tumorigenesis. Examples of these consequences are 
highlighted below.
Transcriptional Regulation
Due to its robust expression levels and long cellular half-life, 
PTEN is thought to be constitutively expressed and minimally 
regulated in normal tissues. This notion is in fact mislead-
ing given that the exact pattern of regulation of PTEN dur-
ing development and adult life is unclear. Furthermore, the 
stability of PTEN may be altered dramatically in pathological 
settings (Figure 2B).
PTEN was originally cloned as a gene transcriptionally 
regulated by transforming growth factor β (TGFβ) Li and Sun, 
1997). Since this discovery, numerous factors have been dem-
onstrated to upregulate PTEN transcription including the per-
oxisome proliferation-activated receptor γ (PPARγ) (Patel et al., 
2001), and the early growth-regulated transcription factor-1 
(EGR-1) (Virolle et al., 2001), which functions downstream of 
insulin-like growth factor 2 (IGF-2) (Moorehead et al., 2003). 
Additionally, Stambolic et al. (2001) identified a putative p53-
binding element in the promoter sequence of PTEN and char-
acterized a p53-mediated cellular survival mechanism that 
functions through the activation of PTEN transcription. Induc-
tion of PTEN may be an important mechanism by which its 
presence is ensured when it is required to perform its tumor 
suppressive function. Unlike the tumor suppressor p53, which 
is acutely and rapidly upregulated in response to potentially 
oncogenic stresses, PTEN expression is constitutive and 
essential at all times.
As previously mentioned, suppression of PTEN transcrip-
tion may have an important and underestimated role in can-
cer (Figure 2B). Indeed, recent studies have demonstrated a 
link between the oncogenic RAS-MAPK pathway and aber-
rant transcriptional downregulation of PTEN in both fibro-
blast and epithelial cell types and in human cancer cells. 
Chow et al. (2007) attribute RAS-mediated PTEN suppres-
sion to a TGFβ-dependent mechanism in pancreatic adeno-
carcinoma and Vasudevan et al. (2007) demonstrate that the 
oncogenic RAS-RAF-MEK-ERK pathway suppresses PTEN 
levels through the transcriptional factor, c-Jun (Hettinger et 
al., 2007). Moreover, other stress kinase pathways including 
MEKK4 and JNK promote resistance to apoptosis by sup-
pressing PTEN transcription via direct binding of NFκB to 
the PTEN promoter (Xia et al., 2007). Conversely, PTEN was 
demonstrated to oppose the JNK pathway (Vivanco et al., 
2007). This finding suggests that pathways that are nega-
tively regulated by PTEN can in turn regulate PTEN tran-
scription, thereby identifying a new and potentially impor-
tant feedback loop.Cell 133, May 2, 2008 ©2008 Elsevier Inc. 405
Finally, recent studies have identified new pathways for 
PTEN regulation occurring downstream of NOTCH1. Active 
NOTCH1 has been reported to increase PTEN transcription 
through mechanisms involving the CBF-1 transcription fac-
tor (Chappell et al., 2005; Whelan et al., 2007) and MYC (Pal-
omero et al., 2007). On the other hand, NOTCH1 activation 
has also been demonstrated to repress PTEN transcription 
through the HES-1 transcription factor (Palomero et al., 2007). 
The function of NOTCH1 on PTEN transcription appears to be 
complex and multifactorial and is most likely tissue specific. 
Palomero et al. (2007) have implicated PTEN in the repres-
sion of the leukemogenic program promoted by NOTCH1 
activation. This work provides the basis for the design of new 
therapeutic strategies for NOTCH1-related leukemia. Taken 
together, these findings suggest that the transcriptional con-
trol of PTEN lies at a key position in a complex network of 
tumor suppressors and oncogenes that regulates cellular 
transformation (Figure 2B).
Epigenetic silencing by promoter 
methylation has also been proposed as a 
process by which PTEN expression can 
be suppressed in various types of can-
cer (Garcia et al., 2004; Goel et al., 2004; 
Kang et al., 2002; Mirmohammadsadegh 
et al., 2006) (Figure 1A). These findings 
must be interpreted with caution given 
that the promoter of a PTEN pseudo-
gene has been shown to be methylated 
(Zysman et al., 2002).
PTEN Regulation by MicroRNAs
MicroRNAs (miRNAs) are endogenous 
short single-stranded RNAs (approxi-
mately 22 nucleotides in length) that 
repress mRNA translation by base-pair-
ing to sequences located in the 3′UTR of 
target mRNAs. Recently, PTEN was reported to be repressed 
by the miRNA miR-21 (Meng et al., 2006, 2007). Importantly, 
miR-21 is one of the most frequently upregulated miRNAs in 
cancer and has been shown to promote proliferation in glio-
blastoma and to inhibit apoptosis in breast cancer cell lines 
(Chan et al., 2005; Si et al., 2007; Volinia et al., 2006). These 
studies suggest that miR-21 exerts its oncogenic activity in 
part through the downregulation of PTEN expression. Although 
this particular field is in its infancy, it is exciting to envision that 
fine-tuners of gene expression such as miRNAs may influence 
cancer through PTEN regulation.
Phosphorylation: The C-Terminal End Rules
Disrupted PTEN protein stability represents an attractive yet 
elusive mechanism underlying its loss in tumors. Numerous 
reports suggest that PTEN stability is regulated by its interac-
tion with other proteins and that it is subject to various post-
translational modifications (Figure 3A). For instance, phospho-
Figure 2. Genetic Alterations and Transcrip-
tional Regulation of PTEN
(A) PTEN was first identified as a tumor suppres-
sor gene frequently lost on human chromosome 
10q23, a locus that is highly susceptible to mu-
tation in primary human cancers and cancer cell 
lines. Recently, PTEN was found to be mutated 
in breast cancers characterized by the loss of the 
DNA repair protein BRCA1 (Saal et al., 2008). Allelic 
losses can result in complete deletion of the PTEN 
locus; point mutations can produce several PTEN 
truncation mutants and functional inactivation of 
PTEN. Several tumor-derived PTEN mutants retain 
partial or complete catalytic function, suggesting 
that alternate mechanisms can lead to inactivation 
of PTEN; for example, the K289E mutation alters 
the localization of the PTEN protein. PTEN silenc-
ing has also been demonstrated to occur through 
promoter methylation and promoter mutation. 
(B) Numerous genes regulate PTEN transcription 
both positively (EGR-1, PPARγ, Myc, and p53) and 
negatively (NFκB, c-Jun, HES, and TGFβ signal-
ing). NOTCH1 may be able to activate or repress 
PTEN transcription depending on the cellular con-
text. Recently, miR-21 was identified as the first 
microRNA to regulate the expression of PTEN.406 Cell 133, May 2, 2008 ©2008 Elsevier Inc.
rylation of PTEN at specific residues in its C-terminal tail have 
been associated with increased stability (Georgescu et al., 
1999; Torres and Pulido, 2001; Vazquez et al., 2000), whereas 
phosphorylation at other sites may decrease protein stability 
(Maccario et al., 2007). Furthermore, phosphorylation of PTEN 
results in decreased catalytic activity toward lipid substrates, 
which may be explained by changes in its ability to interact 
with membranes. In total, a cluster of six phosphorylation sites 
at Thr366, Ser370, Ser380, Thr382, Thr383, and Ser385 are 
involved in modulating PTEN tumor suppressor functions, 
subcellular distribution, and stability (Figure 3A). Despite the 
fact that Ser370 and Ser385 have been identified as the major 
sites for phosphorylation, their mutation has minimal effects 
on PTEN function, whereas mutation of the Ser380, Thr382, 
and Thr383 (collectively referred to as the STT) cluster shows 
more striking consequences for PTEN. Specifically, mutation 
of STT destabilizes PTEN and increases its phosphatase activ-
ity in cells compared to wild-type PTEN (Vazquez et al., 2000). 
It has been proposed that a phosphorylated STT cluster ren-
ders PTEN in a “closed” state, whereas their mutation to the 
nonphosphorylatable alanine (Ala) opens the protein confor-
mation. This increases PTEN activity, enhances its interaction 
with binding partners, and in turn makes PTEN protein more 
unstable (Leslie and Downes, 2004). Based on this, it has been 
hypothesized that PTEN is normally maintained in a phosphory-
lated, inactive state and its activation can be mediated through 
dephosphorylation of the STT cluster. In general, modification 
of the C terminus by phosphorylation is believed to promote 
conformational changes of the PTEN protein (Vazquez et al., 
2001), and tumor-derived C-terminal mutants of PTEN are 
highly susceptible to protein degradation, implying that this 
region acts as an autostabilizing domain.
PTEN Ubiquitination
Ubiquitin-mediated degradation of PTEN has recently been 
reported, suggesting an additional process whereby PTEN 
levels may be downregulated. As described above, PTEN con-
tains two so-called PEST motifs characteristic of short-lived 
proteins that are subject to ubiquitin-mediated degradation by 
the proteasome. Paradoxically, PTEN is a long-lived and sta-
ble protein in normal cells; however, the PEST domains might 
play an important role under pathological circumstances. The 
first study to indicate that PTEN may be regulated through 
this mechanism demonstrated that the half-life of PTEN is 
increased by proteasome inhibition (Torres and Pulido, 2001). 
Thereafter, it was shown that exposure of human bronchial 
cells to zinc ions promoted ubiquitin-dependent degradation 
of PTEN (Wu et al., 2003). In contradiction, some experimental 
conditions demonstrate that inhibitors of the proteasome may 
actually destabilize PTEN protein (Tang and Eng, 2006).
Interestingly, Trotman et al. (2007) identified Lys13 and Lys289 
as two major conserved sites for PTEN ubiquitination (Figure 
3A) and demonstrated that ubiquitin conjugation to these sites 
is indispensable for the nuclear-cytoplasmic shuttling of PTEN. 
Additionally, by employing a biochemical screening strategy 
to identify E3 ligases for PTEN mono- and polyubiquitination, 
Wang et al. (2007) isolated the NEDD4-1 protein. They dem-
onstrated that NEDD4-1 could physically interact with PTEN, Figure 3. Mechanisms Regulating PTEN
(A) PTEN is subject to several posttranslational modifications including phos-
phorylation, acetylation, oxidation, and ubiquitination. Phosphorylation of 
PTEN at T366, S370, S380, T382, T383, and S385 in its C-terminal tail is 
implicated in modulating PTEN tumor suppressor functions, subcellular distri-
bution, and stability. ROCK has also been reported to promote the localization 
of PTEN to the plasma membrane by phosphorylating PTEN at residues S229, 
T322, T319, and T321 in the C2 domain. PTEN interacts with the nuclear 
histone acetyltransferase-associated PCAF protein, which promotes PTEN 
acetylation at K125 and at K128. These modifications decrease the catalytic 
activity of PTEN. The catalytic activity of PTEN is also modulated by oxidation 
by reactive oxygen species, which induces the formation of a disulfide bond 
between the active site Cys124 and Cys71. Ubiquitination of PTEN has also 
been reported on K13 and K289. Mutation of K289 alters PTEN localization. 
(B) PTEN interacting proteins include the kinases CK2, GSK3β (which can 
phosphorylate PTEN at the C terminus), and ROCK (which targets the C2 
domain). PICT1 can also bind to the C-terminal tail of PTEN to promote its 
phosphorylation and stability. PTEN contains a 3 aa C-terminal region that 
is able to bind to proteins containing PDZ domains. The extreme C-terminal 
PDZ domain of PTEN mediates binding to NHERF proteins and MAGI-2, an 
interaction that is inhibited by C-terminal PTEN phosphorylation.Cell 133, May 2, 2008 ©2008 Elsevier Inc. 407
and its overexpression mediates both the mono- and polyu-
biquitination of PTEN (Wang et al., 2007). Perhaps inhibition 
of NEDD4-1 activity may provide an avenue for therapy to 
upregulate PTEN levels in cancer. However, to date, little is 
known about the regulation of NEDD4-1 nor the physiological 
circumstances, during which it can target PTEN for degrada-
tion. Additional human data and in vivo studies are required to 
validate that NEDD4-1 is a bona fide oncogene and that acts 
via the degradation of PTEN. Finally, whether there are other E3 
ligases that target PTEN requires further exploration.
PTEN Acetylation and Oxidation
Acetylation and oxidation comprise other mechanisms by which 
the PTEN protein activity can be regulated (Figure 3A). For 
example, the interaction of PTEN with nuclear histone acetyl-
transferase-associated PCAF (as described below) can pro-
mote PTEN acetylation at Lys125 and Lys128, which negatively 
regulate the catalytic activity of PTEN (Okumura et al., 2006). 
Furthermore, a series of studies demonstrated that the cata-
lytic activity of PTEN could be modulated by reactive oxygen 
species (ROS) (Kwon et al., 2004; Lee et al., 2002; Leslie et al., 
2003; Seo et al., 2005). These studies demonstrate that PTEN 
activity can be abrogated by oxidative stress-induced formation 
of a disulfide bond between the active site Cys124 and Cys71 
(Lee et al., 2002). Inactivation of PTEN was observed with either 
hydrogen peroxide (H2O2) or endogenous ROS production in 
macrophages, where ROS are generated in response to cel-
lular stress and receptor activation, and is associated with an 
oxidant-dependent activation of downstream signaling (Kwon 
et al., 2004; Leslie et al., 2003). Modulation of PTEN activity by 
posttranslational modifications represents a provocative and 
therapeutically exploitable mechanism of PTEN regulation.
PTEN Interacting Proteins
Phosphorylation of the C terminus of PTEN has been attributed 
to the activities of casein kinase 2 (CK2) and glycogen synthase 
kinase 3β (GSK3β) (Al-Khouri et al., 2005; Miller et al., 2002; Torres 
and Pulido, 2001). The C terminus also interacts with PICT1 (pro-
tein interacting with carboxyl-terminus tail 1), which binds to the 
C-terminal tail of PTEN to promote its phosphorylation and stabil-
ity (Okahara et al., 2004). PTEN contains a 3 aa C-terminal region 
that is able to bind to PDZ domain-containing proteins (Georgescu 
et al., 1999; Wu et al., 2000). PDZ domains are involved in the 
assembly of multiprotein complexes. Hence, this region may 
control PTEN localization and interaction with other proteins, 
although the deletion of these amino acids has been reported not 
to alter the tumor suppressive activity of PTEN (Georgescu et al., 
1999). Indeed, the PDZ domain of PTEN mediates interactions 
with Na+ H+ exchanger regulatory factor (NHERF) proteins as well 
as membrane-associated guanylate kinase inverted 2 (MAGI-2). 
These interactions serve to recruit PTEN to the membrane, and 
can be negatively modulated by phosphorylation of PTEN on its 
C terminus (Takahashi et al., 2006; Vazquez et al., 2000, 2001). 
Additionally, there is evidence that the C2 domain of PTEN can 
be phosphorylated by RhoA-associated kinase (ROCK) to acti-
vate and target it to the membrane in leukocytes stimulated by 
chemoattractants (Li et al., 2005). Finally, a repressor of PTEN 
named DJ-1 was identified in a genetic screen in Drosophila. 408 Cell 133, May 2, 2008 ©2008 Elsevier Inc.DJ-1 expression is associated with elevated levels of activated 
AKT and poor clinical outcome in various cancer types, including 
breast, lung, and ovarian carcinoma; however, its mechanism of 
action is still unclear (Davidson et al., 2007; Kim et al., 2005). PTEN 
has many diverse interacting partners suggesting multiple func-
tions for PTEN. Yet, further investigation is needed to understand 
the physiological relevance of many of these interactions.
PTEN in the Nucleus
It was initially assumed that PTEN was exclusively localized 
to the cytoplasm. In agreement with this notion, early reports 
identified a lipid-binding domain and the absence of a canoni-
cal nuclear localization signal (NLS) on the PTEN protein, and 
other studies utilizing overexpression systems and early PTEN 
antibodies demonstrated that PTEN was exclusively in the cyto-
plasm (Lee et al., 1999; Li and Sun, 1997; Whang et al., 1998). 
Soon thereafter, the first lines of evidence for the existence of 
nuclear PTEN were noted in neuronal and breast tissues or cell 
lines with little fanfare (Lachyankar et al., 2000; Sano et al., 
1999). In general, these early observations of nuclear PTEN 
were believed to arise due to artifacts of immunohistochemical 
staining and poor quality antibodies (as reviewed in Lian and 
Di Cristofano [2005]].
Today it is well documented that a pool of PTEN protein is 
localized to and functional within the nucleus. Immunocytologi-
cal and immunohistochemical data with new and reliable PTEN 
antibodies have established the presence of nuclear PTEN in 
neurons (Lachyankar et al., 2000), thyroid tissue (Gimm et al., 
2000), pancreatic cells (Perren et al., 2000), skin (Whiteman et 
al., 2002), esophageal squamous cell carcinoma (Tachibana et 
al., 2002), vascular smooth muscle cells (Deleris et al., 2003), 
and in the intestinal mucosa (Trotman et al., 2007). Specifically, 
PTEN is predominantly localized to the nucleus in primary, dif-
ferentiated, and resting cells, compared to rapidly cycling can-
cer cell lines where in many cases there is a marked reduction 
of nuclear PTEN (Gimm et al., 2000; Ginn-Pease and Eng, 2003; 
Lachyankar et al., 2000; Perren et al., 1999, 2000). Therefore, it 
is surmised that PTEN localization may be dependent not only 
on cell cycle stage, but also on differentiation status.
This new knowledge begs the question of what function can 
be attributed to the nuclear pool of PTEN. Indeed, nuclear-
cytoplasmic partitioning of PTEN is a promising biological 
marker. Indeed, the absence of nuclear PTEN is associated 
with more aggressive disease in patients with esophageal 
squamous cell carcinoma (Tachibana et al., 2002), cutaneous 
melanoma (Whiteman et al., 2002; Zhou et al., 2000), colorectal 
cancer (Zhou et al., 2002), pancreatic islet cell tumors (Perren 
et al., 2000) and cases of large B cell lymphoma (Fridberg et al., 
2007). Therefore, the absence of nuclear PTEN may serve as a 
useful prognostic indicator. In keeping with this concept, forced 
nuclear expression of PTEN opposes anchorage-independent 
growth in transformation assays (Liu et al., 2005b). Together, 
the results of these studies indicate that the tumor suppressive 
function of PTEN is at least in part due to its nuclear function.
PTEN’s Nuclear Family
The presence of both PTEN and PIP3 within the nucleus may 
imply that PTEN functions as a nuclear lipid phosphatase, simi-
lar to its role at cytoplasmic membranes. Unexpectedly, there 
is limited evidence supporting this notion (Deleris et al., 2003), 
and in fact it has recently been reported that only the cyto-
plasmic (and not the nuclear) pool of PIP3 is sensitive to PTEN 
catalysis (Lindsay et al., 2006). Clearly, the hypothesis of a lipid 
phosphatase function of PTEN within the nucleus requires fur-
ther experimentation to be substantiated.
How then might nuclear PTEN act as a tumor suppressor? 
This has become a subject of significant debate, and despite 
several recent studies, this particular question has yet to be 
addressed in full. What we have learned is that unlike cytoplas-
mic PTEN, the effects of nuclear PTEN are likely not mediated 
directly through AKT (Liu et al., 2005b), yet this is at odds with 
the finding that enforced nuclear PTEN expression can reduce 
cellular levels of phosphorylated AKT (Trotman et al., 2007). 
Nuclear PTEN has been proposed to regulate the cell cycle 
through the suppression of cyclin D1 activity by transcriptional 
downregulation or by limiting its nuclear accumulation (Chung 
et al., 2006; Radu et al., 2003). PTEN in the nucleus may also 
act as a proapoptotic factor, as suggested by the observation 
that in cell lines apoptotic stimuli promotes the nuclear accu-
mulation of PTEN (Gil et al., 2006). Nonetheless, it still remains 
unclear as to whether the suppression of cyclin D1 or apopto-
sis is indeed due to a specific nuclear function of PTEN, and 
whether it is lipid phosphatase dependent or independent.
In search of potential nuclear substrates for PTEN, Okumura 
et al. (2005) employed a yeast-two-hybrid approach with the C 
terminus of PTEN and identified the nucleolar proto-oncogene 
MSP58 as a nuclear interacting partner for PTEN (Figure 3B). 
MSP58 was shown to transform Pten null mouse embryonic fibro-
blasts, although this outcome was abrogated in the presence of 
wild-type PTEN and, surprisingly, also by a phosphatase inactive 
PTEN mutant. This report demonstrated that the nuclear tumor 
suppression function of PTEN is lipid phosphatase independent 
and, at least in part, mediated through 
the C-terminal domain. More recently, 
two studies recently reported the interac-
tion of PTEN with nuclear histone acetyl-
transferases PCAF and p300/CBP (Li et 
al., 2006; Okumura et al., 2006). Interest-
ingly, Li et al. (2006) also demonstrated a 
role for nuclear PTEN in promoting p300/
CBP-mediated p53 acetylation in the 
response to DNA damage. These two 
studies provide great insight into a new 
potential mechanism whereby nuclear PTEN controls cellular pro-
liferation by modulating the acetylation of histones and other cel-
lular proteins including p53. As discussed below, p53 maintains a 
complex relationship with PTEN.
Finally, PTEN loss in human primary breast cancer has been 
associated with extensive centromere breakage and chromo-
somal translocations, suggesting a role for PTEN in the mainte-
nance of chromosomal integrity (Puc and Parsons, 2005; Shen 
et al., 2007). In one study, this was attributed to AKT-mediated 
phosphorylation of CHK1, an event that leads to the sequestra-
tion of this DNA-damage checkpoint protein from the nucleus 
(Puc and Parsons, 2005). In a recent follow up study, Shen 
et al. (2007) have identified new mechanisms by which PTEN 
can maintain chromosomal stability. First, PTEN was found 
to associate with the centromere by docking onto CENP-C, a 
centromeric binding protein (Figure 4). A phosphatase-inactive 
mutant of PTEN could also bind CENP-C suggesting that this 
association is phosphatase independent. A Cowden syndrom 
and tumor-derived PTEN mutant protein lacking the C terminus 
inhibited the PTEN-CENP-C interaction and induced chromo-
somal instability. Second, PTEN was shown to control DNA 
repair through it ability to regulate the transcription of Rad51, 
a key protein involved in double-strand break repair (Figure 4). 
Hence, there is evidence for an important nuclear function of 
PTEN that is C terminus dependent, phosphatase indepen-
dent, and multifactorial and complex in nature.
Mechanisms of Nuclear Localization
The appropriate cytoplasmic and nuclear partitioning of PTEN is 
critical for its diverse biological functions (Figure 4). It was recently 
reported that nuclear import of PTEN is cell cycle dependent and 
regulated by the PI3K/Akt/mTOR/S6K signaling cascade (Liu 
et al., 2007). Importantly, the mechanisms for nuclear import of 
PTEN are unclear, largely due to the lack of functional and trans-
Figure 4. Functions of Nuclear PTEN
PTEN tumor suppressive activity is not restricted 
to its cytoplasmic function, which is to oppose 
the PI3K signaling pathway. It has been proposed 
that PTEN can translocate into the nucleus 
through various mechanisms including passive 
diffusion, Ran- or MVP-mediated import, and a 
monoubiquitination-driven mechanism. In the 
nucleus, the physiological role of PTEN may not 
be related to PIP3 hydrolysis but instead to other 
functions including regulation of chromosomal 
integrity, p53 acetylation, cell cycle progression, 
the induction of apoptosis, and the DNA-damage 
response through the regulation of RAD51.Cell 133, May 2, 2008 ©2008 Elsevier Inc. 409
ferable NLS (Trotman et al., 2007). To date PTEN localization has 
been attributed to various mechanisms, including a calcium-
dependent interaction of the major vault protein with two puta-
tive bipartite NLS sequences within PTEN (Chung et al., 2005; 
Minaguchi et al., 2006), passive diffusion (Liu et al., 2005a), the 
existence of various nuclear exclusion sequences, and a nuclear 
localization domain and Ran-dependant mechanism that governs 
the interplay between these motifs (Gil et al., 2006). Conversely, 
the nuclear export of PTEN has been reported to occur via a 
CRM1-dependent mechanism activated by the PI3K/AKT path-
way; however, the lack of a conventional nuclear export signal 
suggests that PTEN may be exported in association with another 
NLS-containing molecule (Liu et al., 2007).
The examination of a cancer-associated germline mutation of 
PTEN sheds light on a ubiquitination-dependent mechanism of 
PTEN nuclear transport. Indeed, a recent study demonstrated 
that inhibition of ubiquitin conjugation by mutation of critical lysine 
residues on PTEN has tremendous consequences for PTEN 
localization and tumorigenesis (Trotman et al., 2007). The notion 
of ubiquitin dependency for localization requires the existence of 
enzymes that can actively ubiquitinate PTEN and correspondingly 
implies that enzymes that can deubiquitinate PTEN can also play 
an important role in PTEN localization. To date, only the E3-ligase 
NEDD4-1 has been reported to ubiquitinate PTEN. On the other 
hand no deubiquitinating enzymes (DUBs) have yet been iden-
tified to oppose this function. Importantly, the manipulation of 
PTEN localization may provide a promising strategy for cancer 
treatment. Further research into this feature of PTEN regulation 
will indeed shed light on ways to exploit this mechanism.
AKT-Independent Roles of PTEN
Most of the phenotypes associated with PTEN loss can be 
explained by the activation of the PI3K/AKT pathway, although 
this is not always the case. For example, Pten null prostates 
eventually develop invasive prostate cancer. However, trans-
genic models with prostate-specific overexpression of a consti-
tutively active AKT develop only localized and, for the most part, 
preneoplastic lesions (Majumder et al., 2003; Trotman et al., 
2003). Discrepancies between other mouse models of Pten loss 
and Akt overexpression has been the subject of a recent review 
(Blanco-Aparicio et al., 2007). Taken together, it is increasingly 
evident that PTEN possesses functions that are independent of 
its ability to specifically suppress the PI3K pathway.
Most recently, Vivanco et al. (2007) utilized a comprehensive 
transcriptional profiling methodology to identify new PTEN-
regulated pathways. The authors demonstrated that the Jun-N-
terminal Kinase (JNK) pathway was consistently activated upon 
PTEN knockdown in an AKT-independent manner. In addition 
to finding alternative pathways activated subsequent to PTEN 
loss, these findings provide important clinical clues suggesting 
that inhibitors of the AKT pathway could be combined with JNK 
pathway inhibition for improved efficacy in PTEN null cancers.
Lipid Phosphatase-Independent Roles of PTEN
Although PTEN is thought to function predominantly as a lipid 
phosphatase, lipid phosphatase-independent roles have been 
reported. For instance, the ability of PTEN to directly dephospho-
rylate residues on FAK was shown to oppose cell migration by 410 Cell 133, May 2, 2008 ©2008 Elsevier Inc.negatively regulating interactions with the cellular matrix (Tamura 
et al., 1998). However, FAK phosphorylation was unchanged in 
Pten null cells, and a second study was unable to show either 
a direct interaction of FAK and PTEN or FAK dephosphorylation 
upon PTEN overexpression (Maier et al., 1999; Sun et al., 1999). 
Additionally, the physiological relevance of PTEN-mediated FAK 
dephosphorylation is currently unclear. More recently, as dis-
cussed above, PTEN loss has been shown to have detrimental 
effects on genomic stability (Shen et al., 2007). Numerous studies 
have demonstrated a complex and uncertain relationship between 
p53 and PTEN. In one study, PTEN has been reported to bind 
to p53 directly, and as a consequence it increases p53 protein 
levels by modulating its stability and increasing its transcription. 
The half-life of p53 in Pten null mouse embryonic fibroblasts was 
dramatically compromised. Interestingly, this relationship was 
demonstrated to be independent of PTEN phosphatase function 
given that catalytically inactive mutants were capable of stabiliz-
ing p53 in Pten null cells (Freeman et al., 2003). However, other 
studies have reported that PTEN inactivation results in a rapid and 
marked upregulation of p53 (Chen et al., 2005). Hence, a thorough 
analysis of this controversial issue is warranted to understand the 
role of the PTEN and p53 crosstalk in tumorigenesis.
PTEN and Stem Cell Maintenance
The first lines of evidence demonstrating that PTEN may also 
play a role in stem cell homeostasis came from the studies of 
Pten loss in murine neuronal tissues (Backman et al., 2001; 
Groszer et al., 2001; Kwon et al., 2001). Utilizing independent 
mouse models, three groups demonstrated that specific dele-
tion of Pten from the mouse brain led to enlarged brains (mac-
rocephaly) with severely disturbed patterning of brain struc-
tures. This phenotype appeared to result from a combination 
of increased cell number, decreased cell death, and enlarged 
neuronal cell size. In ex vivo experiments, it was demonstrated 
that Pten loss does not alter neuronal cell fate but, instead, 
increases the total number of neurons in the fetal brain and the 
number of neuronal stem cells that were capable of growth in 
cell culture experiments. This consequence of Pten loss was 
later reported to result from an enhanced self-renewal capacity 
and G0-G1 cell cycle entry and decreased growth factor depen-
dency of Pten null neural/stem progenitor cells (Groszer et al., 
2006). In conclusion, Pten deficiency in neuronal stem cells 
provides a strong proliferative stimulus and promotes a greatly 
enhanced self-renewal capacity.
More recently, two groups demonstrated that PTEN has a role 
in the maintenance of the hematopoietic stem cell (HSC) (Yilmaz 
et al., 2006; Zhang et al., 2006). Conditional deletion of Pten in 
the murine hematopoietic system resulted in the exhaustion of 
normal HSCs and promoted the excessive proliferation of leuke-
mogenic stem cells resulting in the development of myeloprolif-
erative disorders and eventually leukemia. Furthermore, Yilmaz 
et al. (2006) demonstrated that treatment of Pten-deficient cells 
and mice with the mTOR inhibitor rapamycin effectively blocked 
the growth of the leukemogenic stem cell and at the same time 
prevented the exhaustion of normal HSCs. These findings may 
have a tremendous impact for the treatment of stem cells disor-
ders that are leukemogenic in nature, in particular those arising 
from disorders in the PTEN/PI3K pathway.
Notably, the mechanism for exhaustion or loss of HSCs sub-
sequent to Pten deletion is currently unknown. Similar to the 
observations in mouse prostate (Chen et al., 2005), Pten defi-
ciency may trigger a protective p53-dependent senescence 
apoptotic response that will ultimately deplete the HSC pool. In 
the same way, the excessive growth of leukemic cells may arise 
due to selective evasion of this failsafe senescence mechanism 
because of secondary mutations (in p53, for example) aris-
ing from the genomic instability induced by the loss of Pten. 
Importantly, the finding that the mTOR inhibitor rapamycin is 
very effective at inhibiting both HSC depletion and leukemia 
has two important implications: (1) the mTOR pathway is highly 
active in leukemia linked to Pten loss, and (2) mTOR is a cen-
tral player in the mechanism leading to the exhaustion of Pten-
deficient HSCs.
Finally, the different stem cell phenotypes observed upon 
Pten-deletions may appear to be at odds in different organs. 
This discrepancy may be explained by a differential capac-
ity of a given organ system to trigger a failsafe mechanism in 
response to Pten loss. For example, it is likely that neuronal 
stem cells do not activate senescence upon Pten loss. In con-
trast, a senescence response or an apoptotic response in 
HSCs can lead to reduced proliferation and exhaustion; when 
selected against by mutation, leukemia undoubtedly arises.
Future Directions
Ten years after its identification, dramatic progress has been 
made in defining the role of PTEN in tumor suppression. PTEN 
is likely to surpass p53 as the most commonly mutated tumor 
suppressor gene in human cancer and represents, from a 
biological standpoint, the first and only known example of a 
lipid phosphatase with bona fide tumor suppressive activity. In 
vivo analysis of mouse models have identified critical conse-
quences of Pten functional inactivation in cancer pathogenesis. 
Pten mouse mutants have become invaluable tools in cancer 
research and in preclinical trials by virtue of their pleiotropic 
tumor-prone phenotype. Pten has been identified as a haploin-
sufficient tumor suppressor protein in mouse models, and the 
realization that slight variations in the amount of PTEN protein 
can have tremendous consequences for tumor initiation and 
cancer susceptibility underscores the importance of defining 
the regulatory mechanisms that control PTEN function. Pten 
also acts in the nucleus and has been ascribed functions that 
go beyond its phosphate activity. Pten may be essential and 
nonredundant, although other kinases and phosphatases that 
are able to modulate the PI3K/AKT pathway may also be criti-
cal in tumorigenesis. This progress has in turn raised further 
exciting questions from both a genetic and mechanistic view-
point concerning the precise function and the specific regu-
lation of this critical tumor suppressor in human cancer sus-
ceptibility. In general, PTEN is robustly expressed in normal 
cells and mechanisms that regulate PTEN expression, protein 
levels, and cellular trafficking are largely undiscovered. How-
ever, in the course of a wide range of pathological conditions 
PTEN can be downregulated by various mechanisms including 
genetic mutation, transcription, translation, and posttransla-
tional modification. Furthermore, the PTEN/PI3K/AKT pathway 
is amenable to pharmacological manipulation, and PTEN itself may become a “druggable” target in the near future, as is cur-
rently the case for p53 (Nahi et al., 2008; Vassilev et al., 2004). 
Functional analysis of PTEN domains through mutation, the dis-
covery of new regulators of PTEN, and a greater understanding 
of the regulatory networks that influence PTEN expression in 
vitro and in vivo will be critical in unraveling additional PTEN 
functions. In view of the key role exerted by PTEN in opposing 
tumorigenesis and in embryonic development, further elucida-
tion of PTEN function will remain a major focus of research in 
the years to come.
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